Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patientsreceiving high-dose intravenous interleukin-2
Autore:
Ohnmacht, GA; Phan, GQ; Mavroukakis, SA; Steinberg, SM; Shea, YR; Witebsky, FG; McIntyre, LS; Goodwin, RS; Muehlbauer, PM; Morton, KE; Rogers-Freezer, LJ; Seipp, CA; Rosenberg, SA; Marincola, FM;
Indirizzi:
NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI, Biostat & Data Management Sect, Div Clin Sci, NIH, Bethesda, MD 20892USA NCI Bethesda MD USA 20892 Sect, Div Clin Sci, NIH, Bethesda, MD 20892USA NIH, Dept Clin Pathol, Ctr Clin, Bethesda, MD 20892 USA NIH Bethesda MD USA 20892 t Clin Pathol, Ctr Clin, Bethesda, MD 20892 USA NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA NIH Bethesda MD USA 20892 Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA NIH, Ctr Clin, Dept Transfus Med, Bethesda, MD 20892 USA NIH Bethesda MD USA 20892 Clin, Dept Transfus Med, Bethesda, MD 20892 USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 2, volume: 24, anno: 2001,
pagine: 188 - 192
SICI:
1524-9557(200103/04)24:2<188:APRDPT>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANDIDIASIS; TOXICITY; CANCER;
Keywords:
interleukin-2; nystatin; thrush; oral pain; oral irritation; prospective randomized trial; placebo;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Marincola, FM NCI, Surg Branch, NIH, Bldg 10,Room 2B56,10 Ctr Dr,MSC 1502,Bethesda, MD 20892 USA NCI Bldg 10,Room 2B56,10 Ctr Dr,MSC 1502 Bethesda MD USA 20892
Citazione:
G.A. Ohnmacht et al., "A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patientsreceiving high-dose intravenous interleukin-2", J IMMUNOTH, 24(2), 2001, pp. 188-192

Abstract

Interleukin-2 (IL-2) has been used to treat patients with metastatic melanoma and renal cell cancer for nearly two decades, and much progress has been made in ameliorating its adverse effects. One bothersome adverse effect, oral pain ol oral irritation, is usually treated with an oral antifungal antibiotic, nystatin. The authors performed a prospective, randomized, double-blind, placebo-controlled trial involving 64 patients to evaluate the effect of prophylactic administration of nystatin or placebo on the developmentof oral irritation in patients receiving high-dose intravenous IL-2. No difference was found between patients randomized to receive nystatin or placebo in their rates of development of oral irritation, the severity of IL-2 adverse effects, the duration of their treatment, the rate of development ofpositive studies for oral yeast, or their pattern of experiencing other adverse effects. Thus, patients who receive high-dose intravenous IL-2 shouldnot be treated prophylactically with nystatin to prevent oral irritation, and clinicians should seek evidence of the presence of oral thrush before using antifungal agents to treat oral pain in these patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:45:47